Human medicines European public assessment report (EPAR): Imatinib Koanaa, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Myelodysplastic-Myeloproliferative Diseases;Hypereosinophilic Syndrome;De

Human medicines European public assessment report (EPAR): Imatinib Koanaa, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Myelodysplastic-Myeloproliferative Diseases;Hypereosinophilic Syndrome;Dermatofibrosarcoma;Gastrointestinal Stromal Tumors, Date of authorisation: 22/09/2021, Status: Withdrawn